Neose Technologies Inc has entered into a collaboration agreement with Sandoz. Under the agreement, Neose will use its technologies with a therapeutic recombinant protein which is manufactured and supplied by Sandoz.

If both parties elect to proceed with further development and commercialization, they would have co-exclusive worldwide rights.

Neose is a biopharmaceutical company focused on the improvement of protein therapeutics through the application of its proprietary technologies. By leveraging its GlycoAdvance and GlycoPEGylation technologies, Neose is developing proprietary protein drugs that are improved versions of currently marketed therapeutics with proven efficacy.

Sandoz, a Novartis company, is a global producer of generic pharmaceuticals and develops, manufactures and sells these medicines and pharmaceuticals and biotechnological active ingredients.